Sarepta Therapeutics (SRPT) Gets a Buy from Wells Fargo

Tip Ranks
2025.11.26 12:28
portai
I'm PortAI, I can summarize articles.

Wells Fargo analyst Yanan Zhu maintained a Buy rating on Sarepta Therapeutics with a $45 price target. Zhu, who covers the Healthcare sector, has an average return of 9.6% and a 37.17% success rate. Mizuho Securities also issued a Buy rating, while Bernstein maintained a Hold rating on Sarepta Therapeutics.

Wells Fargo analyst Yanan Zhu maintained a Buy rating on Sarepta Therapeutics today and set a price target of $45.00.

TipRanks Black Friday Sale

  • Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
  • Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

Zhu covers the Healthcare sector, focusing on stocks such as Avidity Biosciences, uniQure, and Intellia Therapeutics. According to TipRanks, Zhu has an average return of 9.6% and a 37.17% success rate on recommended stocks.

In addition to Wells Fargo, Sarepta Therapeutics also received a Buy from Mizuho Securities’s Uy Ear in a report issued on November 16. However, yesterday, Bernstein maintained a Hold rating on Sarepta Therapeutics (NASDAQ: SRPT).

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer